Replies to post #251035 on Biotech Values

[Mufaso]

Yes, that is something that makes the weight loss look better. Other comments are that phase 1 studies are prone to sampling error. Also, I'd like to know male vs female split (Female more likely to lose weight in study) .

I'm much more interested in tolerability/side effects. I think they are hiding something there. Why not release the data? If that was good, they would have released it. Instead they have been pretty coy. I just saw ,Novo Nordisk's Executive Vice President, Development, Martin Holst Lange made some comments:

After 12 weeks on amycretin in the trial, more than 80% of the participants were still on the drug, Lange said, describing it as an "impressive" retention rate which would suggest that the doses were safe and patients were tolerating it well without major side effects.

https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-hopes-launch-experimental-obesity-drug-within-this-decade-2024-03-08/

Ok so now discontinuation rate was around 20% which isn't bad but its not great either. Guess he didn't want to say if AE's were mild or moderate or if they had any SAE's that led to discontinuation.